The Progression of Regenerative Medicine and its Impact on Therapy Translation

Despite regenerative medicine (RM) being one of the hottest topics in biotechnology for the past 3 decades, it is generally acknowledged that the field’s performance at the bedside has been somewhat disappointing. This may be linked to the novelty of these technologies and their disruptive nature, w...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational science 2020-05, Vol.13 (3), p.440-450
Main Authors: Jacques, Erik, Suuronen, Erik J.
Format: Article
Language:English
Subjects:
Biotechnology
Forecasting
History, 19th Century
History, 20th Century
History, 21st Century
Humans
Medicine
Mythology
Regenerative medicine
Regenerative Medicine - ethics
Regenerative Medicine - history
Regenerative Medicine - legislation & jurisprudence
Regenerative Medicine - trends
Researchers
Review
Skin
Studies
Therapeutic applications
Tissue engineering
Translation
Translational Research, Biomedical - ethics
Translational Research, Biomedical - history
Translational Research, Biomedical - legislation & jurisprudence
Translational Research, Biomedical - trends
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite regenerative medicine (RM) being one of the hottest topics in biotechnology for the past 3 decades, it is generally acknowledged that the field’s performance at the bedside has been somewhat disappointing. This may be linked to the novelty of these technologies and their disruptive nature, which has brought an increasing level of complexity to translation. Therefore, we look at how the historical development of the RM field has changed the translational strategy. Specifically, we explore how the pursuit of such novel regenerative therapies has changed the way experts aim to translate their ideas into clinical applications, and then identify areas that need to be corrected or reinforced in order for these therapies to eventually be incorporated into the standard‐of‐care. This is then linked to a discussion of the preclinical and postclinical challenges remaining today, which offer insights that can contribute to the future progression of RM.
ISSN:1752-8054
1752-8062
DOI:10.1111/cts.12736